| __timestamp | Bristol-Myers Squibb Company | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 1213000 |
| Thursday, January 1, 2015 | 5001000000 | 3425000 |
| Friday, January 1, 2016 | 5002000000 | 6311000 |
| Sunday, January 1, 2017 | 4849000000 | 9518000 |
| Monday, January 1, 2018 | 4551000000 | 28080000 |
| Tuesday, January 1, 2019 | 4871000000 | 36550000 |
| Wednesday, January 1, 2020 | 7661000000 | 46125000 |
| Friday, January 1, 2021 | 7690000000 | 68486000 |
| Saturday, January 1, 2022 | 7814000000 | 92032000 |
| Sunday, January 1, 2023 | 7772000000 | 117532000 |
| Monday, January 1, 2024 | 8414000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Bristol-Myers Squibb Company (BMY) and Rhythm Pharmaceuticals, Inc. (RYTM) have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BMY's SG&A expenses have surged by approximately 36%, peaking in 2022. This reflects their expansive market strategies and robust operational scale. In contrast, RYTM, a smaller player, has seen a staggering 9,600% increase in SG&A expenses, highlighting their aggressive growth and market penetration efforts. While BMY's expenses are consistently in the billions, RYTM's rise from a modest base underscores their dynamic expansion. This comparison not only illustrates the diverse strategies of these companies but also offers insights into their future trajectories in the competitive pharmaceutical landscape.
Eli Lilly and Company or Rhythm Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Rhythm Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Analyzing R&D Budgets: Bristol-Myers Squibb Company vs Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Viking Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Bristol-Myers Squibb Company vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Rhythm Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Opthea Limited vs Rhythm Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing CRISPR Therapeutics AG and Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?